Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Category: #health  By Mateen Dalal  Date: 2019-07-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin

Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristol-Meyers Squibb has initiated a Phase 1 clinical trial in order to evaluate the safety, pharmacodynamics and pharmacokinetics of Relaxin, which is a long-acting and a potential heart failure treatment.

Reportedly, long-acting Relaxin happens to be an investigational biologic that is produced using the proprietary expanded genetic code platform from Ambrx. Heart failure affects 15 million people around the world and is a life-threatening and debilitating health condition.

President and CEO of Ambrx, Dr. Feng Tian said that the company believes long-acting Relaxin signifies a new therapeutic option to treat heart failure. The new trial is the second program from the company’s collaboration with Bristol-Myers Squibb which has been able to reach clinical testing, both of which have been enabled by the company’s platform technology.

The first program is a long acting FGF21 which is in Phase 2b to treat NASH. Both of these programs carry substantial value to Ambrx and the company appreciates Bristol-Myers Squibb as their partner, Tian added.

According to reports, under the 2011 Collaboration and License Agreement for Relaxin with Bristol-Myers Squibb, Ambrx will be paid a milestone payment with the initiation of the study. The terms of the agreement list that Ambrx will be eligible to receive additional payment for development including the royalties on annual net sales for any products related to Relaxin.

Apparently, Relaxin’s derivatives were developed using the expanded genetic code platform tech of Ambrx which incorporates non-native amino acid in the hormones. The non-natural amino acid is often used as chemical modification site for the engineering of precise protein which enhances Relaxin’s pharmaceutical or therapeutic properties and in this case, extends the circulating half-life of the hormone.

 

Source Credit- http://ambrx.com/wp-content/uploads/2019/07/Ambrx-BMS-Relaxin_-Ph1-Ambrx_final_new_BMS-edit.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...

Saepio, Echoworx partner to deliver Next-Gen security solutions
Saepio, Echoworx partner to deliver Next-Gen security solutions
By Mateen Dalal

Saepio Information Security, a market leader in statement encryption and cloud-based email, has reportedly announced its collaboration with Echoworx to offer next-generation safe delivery of sensitive and secret information to any email receiver...

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...